Skip to main content

Table 2 Effect of krill powder supplementation on plasma esterified fatty acid composition in obese men (N = 11) at baseline, the middle and end of the study

From: Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men

Fatty acid

Baseline

Week 12

Week 24

C12:0

0.10 ± 0.05

0.12 ± 0.07

0.12 ± 0.11

C14:0

1.25 ± 0.41

1.18 ± 0.41

1.19 ± 0.56

C15:0

0.20 ± 0.04

0.19 ± 0.04

0.20 ± 0.05

C16:0

23.27 ± 2.53

22.28 ± 2.41

22.78 ± 3.10

C16:1

2.49 ± 0.52

2.03 ± 0.59 **

2.19 ± 0.82

C18:0

6.56 ± 0.37

6.45 ± 0.46

6.42 ± 0.41

C18:1,t6-11

0.35 ± 0.13

0.47 ± 0.32

0.35 ± 0.14

C18:1,c9

23.10 ± 2.54

22.06 ± 2.05

21.54 ± 2.21 **

C18:1,c11

1.56 ± 0.29

1.52 ± 0.21

1.56 ± 0.25

C18:2,n-6

23.11 ± 3.78

25.25 ± 4.06 **

24.37 ± 4.99

C20:0

0.25 ± 0.05

0.25 ± 0.04

0.25 ± 0.05

C18:3,n-6

0.45 ± 0.18

0.37 ± 0.09

0.35 ± 0.09

C18:3,n-3

0.73 ± 0.30

0.75 ± 0.26

0.73 ± 0.19

C20:1,n-9

0.15 ± 0.05

0.15 ± 0.04

0.16 ± 0.04

C20:2,n-6

0.19 ± 0.04

0.18 ± 0.03

0.17 ± 0.04

C22:0

0.56 ± 0.13

0.60 ± 0.14

0.60 ± 0.16

C20:3,n-6

1.51 ± 0.21

1.33 ± 0.17 *

1.38 ± 0.15 *

C20:4,n-6 (AA)

4.85 ± 1.15

5.00 ± 0.78

5.30 ± 1.13

C20:4,n-3

0.10 ± 0.04

0.10 ± 0.03

0.09 ± 0.03

C20:5,n-3 (EPA)

0.75 ± 0.24

1.24 ± 0.20 ***

1.15 ± 0.43 ***

C24:0

0.54 ± 0.15

0.54 ± 0.16

0.54 ± 0.16

C24:1

1.00 ± 0.30

1.02 ± 0.19

1.04 ± 0.29

C22:5,n-3

0.47 ± 0.08

0.53 ± 0.08 *

0.52 ± 0.08 *

C22:6,n-3 (DHA)

1.37 ± 0.32

1.67 ± 0.37 *

1.72 ± 0.28 ***

  1. Data are expressed as mean g/100g FAME in plasma ± S.D. P-value was calculated at week 12 and 24 vs. baseline using a paired T-test. *, P < 0.05; **, P < 0.01; ***, P < 0.005 vs baseline.